Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials

Kao et al., 2022 | Dermatol Ther | Other

Citation

Kao Yung-Shuo, Lo Chen-Hsu, ... Hung Cheng-Hsien. Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials. Dermatol Ther. 2022-Oct;35(10):e15774. doi:10.1111/dth.15774

Abstract

Capecitabine-induced hand-foot syndrome (HFS) is common in clinical practice. There are many regimens used to prevent HFS. However, the most effective preventive regimen has not yet been identified. Thus, we conducted a network meta-analysis to investigate the best preventive regimen for HFS. The PRISMA-NMA guidelines were used in this study. The PubMed, Cochrane, and Embase databases were searched. The main endpoint was set as HFS of National Cancer Institute grade 2 or more. We included only randomized control trials. The P-score was used to rank the regimens. Among all the regimens, topical silymarin had the best preventive ability compared with the placebo (OR: 0.08; 95% CI: 0.01-0.71). The other identified effective regimen included pyridoxine (400 mg) and celecoxib; compared with the placebo, the odds ratio was 0.27 (95% CI: 0.08-0.91) and 0.41 (95% CI: 0.18-0.95), respectively. Topical silymarin is the most useful regimen for preventing capecitabine-induced HFS.

Key Findings

Topical silymarin is the most useful regimen for preventing capecitabine-induced HFS.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Antimetabolites, Antineoplastic
  • Capecitabine
  • Celecoxib
  • Hand-Foot Syndrome
  • Humans
  • Pyridoxine
  • Randomized Controlled Trials as Topic
  • Silymarin

Evidence Classification

  • Level: Other
  • Publication Types: Journal Article, Network Meta-Analysis
  • Vertical: vitamin-b6

Provenance


Source extracted via PubMed E-utilities API on 2026-04-09